Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment

References

• Kessel D. Photodynamic therapy: a brief history. J Clin Med. 2019;8(10):1581. doi:10.3390/jcm8101581.
   PubMed Web of Science ®Google Scholar
• Kessel D, Thomas J. Dougherty: an appreciation. Photochem Photobiol. 2020;96(3):454–20. doi:10.1111/php.13144.
   PubMed Web of Science ®Google Scholar
• Dabrowski JM, Arnaut LG. Photodynamic therapy (PDT) of cancer: from local to systemic treatment. Photochem Photobiol Sci. 2015;14(10):1765–1780. doi:10.1039/c5pp00132c.
   PubMed Web of Science ®Google Scholar
• Aroso RT, Schaberle FA, Arnaut LG, Pereira MM. Photodynamic disinfection and its role in controlling infectious diseases. Photochem Photobiol Sci. 2021;20(11):1497–1545. doi:10.1007/s43630-021-00102-1.
   PubMed Web of Science ®Google Scholar
• Chen B, Pogue BW, Hoopes PJ, Hasan T. Vascular and cellular targeting for photodynamic therapy. Crit Rev Eukaryot Gene Expr. 2006;16(4):279–306. doi:10.1615/CritRevEukarGeneExpr.v16.i4.10.
   PubMed Web of Science ®Google Scholar
• Rocha LB, Gomes-da-Silva LC, Dąbrowski JM, Arnaut LG. Elimination of primary tumours and control of metastasis with rationally designed bacteriochlorin photodynamic therapy regimens. Eur J Cancer. 2015;51(13):1822–1830. doi:10.1016/j.ejca.2015.06.002.
   PubMed Web of Science ®Google Scholar
• Kalka K, Merk H, Mukhtar H. Photodynamic therapy in dermatology. J Am Acad Dermatol. 2000;42(3):389–413. doi:10.1016/S0190-9622(00)90209-3.
   PubMed Web of Science ®Google Scholar
• Intelligence M. Photodynamic therapy market - growth, trends, COVID-19, impact, and forecasts (2023-2028). Accessed 2023 April, 2. https://www.mordorintelligence.com/industry-reports/photodynamic-therapy-market%0A
   Google Scholar
• Report TM Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031. Accessed 2023 April 2. https://www.transparencymarketresearch.com/photodynamic-therapy-market.html
   Google Scholar
• Beljanski V. Photofrin. XPharm: Compr Pharmacol Ref. 2007:1–4. Elsevier. 10.1016/B978-008055232-3.63713-4.
   Google Scholar
• Sharman WM, Allen CM, van Lier JE. Photodynamic therapeutics: basic principles and clinical applications. Drug Discov Today. 1999;4(11):507–517. doi:10.1016/S1359-6446(99)01412-9.
   PubMed Web of Science ®Google Scholar
• Pereira SP, Ayaru L, Ackroyd R, Mitton D, Fullarton G, Zammit M, Grzebieniak Z, Messmann H, Ortner M-A, Gao L, et al. The pharmacokinetics and safety of porfimer after repeated administration 30-45 days apart to patients undergoing photodynamic therapy. Aliment Pharmacol Ther. 2010;32(6):821–827. doi:10.1111/j.1365-2036.2010.04400.x.
   PubMed Web of Science ®Google Scholar
• Bellnier DA, Greco WR, Loewen GM, Nava H, Oseroff AR, Dougherty TJ. Clinical Pharmacokinetics of the PDT Photosensitizers Porfimer Sodium (Photofrin), 2-[1-Hexyloxyethyl]-2-Devinyl Pyropheophorbide-a (Photochlor) and 5-ALA-Induced Protoporphyrin IX. Lasers Surg Med. 2006;38(5):439–444. doi:10.1002/lsm.20340.
   PubMed Web of Science ®Google Scholar
• Grahn MF, McGuinness A, Benzie R, Boyle R, de Jode ML, Dilkes MG, Abbas B, Williams NS. Intracellular uptake, absorption spectrum and stability of the bacteriochlorin photosensitizer 5,10,15, 20-tetrakis (m-hydroxyphenyl) bacteriochlorin (mTHPBC). Comparison with 5,10,15,20-tetrakis (m-hydroxyphenyl) chlorin (mTHPC). J Photochem Photobiol B Biol. 1997;37(3):261–266. doi:10.1016/S1011-1344(96)07421-0.
   Web of Science ®Google Scholar
• Spikes JD, Bommer JC. Photosensitizing properties of mono-l-aspartyl chlorin e6 (NPe6): a candidate sensitizer for the photodynamic therapy of tumors. J Photochem Photobiol B. 1993;17(2):135–143. doi:10.1016/1011-1344(93)80006-U.
   PubMed Web of Science ®Google Scholar
• Senge MO, Brandt JC. Temoporfin (Foscan®, 5,10,15,20-Tetra(m-hydroxyphenyl)chlorin)-A Second-generation Photosensitizer†,‡. Photochem Photobiol. 2011;87(6):1240–1296. doi:10.1111/j.1751-1097.2011.00986.x.
   PubMed Web of Science ®Google Scholar
• Kato H, Furukawa K, Sato M, Okunaka T, Kusunoki Y, Kawahara M, Fukuoka M, Miyazawa T, Yana T, Matsui K, et al. Phase II clinical study of photodynamic therapy using mono-l-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung. Lung Cancer. 2003;42(1):103–111. doi:10.1016/S0169-5002(03)00242-3.
   PubMed Web of Science ®Google Scholar
• Edrei R, Gottfried V, Van Lier JE, Kimel S. Sulfonated Phthalocyanines: photophysical properties, in vitro cell uptake and structure-activity relationships. J Porphyr Phthalocyanines. 1998;2(03):191–199. doi:10.1002/(SICI)1099-1409(199805/06)2:3<191:AID-JPP65>3.0.CO;2-4.
   Google Scholar
• Sokolov VV, Chissov VI, Yakubovskaya RI, Aristarkhova E.I, Filonenko E.V, Belous T.A, Vorozhtsov G.N, Zharkova N.N, Smirnov V.V, Zhitkova M.B. Photodynamic therapy (PDT) of malignant tumors by photosensitzer photosens: results of 45 clinical cases. In: Ehrenberg B, Jori G Moan J editors; 1996. pp. 281–287. 10.1117/12.230943.
   Google Scholar
• Sekkat N, Bergh HVD, Nyokong T, Lange N. Like a bolt from the blue: phthalocyanines in biomedical optics. Molecules. 2011;17(1):98–144. doi:10.3390/molecules17010098.
   PubMed Web of Science ®Google Scholar
• Gierlich P, Mata AI, Donohoe C, Brito RMM, Senge MO, Gomes-da-Silva LC. Ligand-targeted delivery of photosensitizers for cancer treatment. Molecules. 2020;25(22):5317. doi:10.3390/molecules25225317.
   PubMed Web of Science ®Google Scholar
• Sandland J, Boyle RW. Photosensitizer Antibody–Drug Conjugates: past, Present, and Future. Bioconjug Chem. 2019;30(4):975–993. doi:10.1021/acs.bioconjchem.9b00055.
   PubMed Web of Science ®Google Scholar
• Gomes-da-Silva LC, Kepp O, Kroemer G. Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death. Oncoimmunology. 2020;9(1). doi:10.1080/2162402X.2020.1841393.
   PubMed Web of Science ®Google Scholar
• Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011;17(12):1685–1691. doi:10.1038/nm.2554.
   PubMed Web of Science ®Google Scholar
• Furusawa A, Choyke PL, Kobayashi H. NIR-PIT: will it become a standard cancer treatment? Front Oncol. 2022;12:12. doi:10.3389/fonc.2022.1008162.
   Web of Science ®Google Scholar
• Jeffes E. Levulan ®: the first approved topical photosensitizer for the treatment of actinic keratosis. J Dermatolog Treat. 2002;13(sup1):s19–s23. doi:10.1080/095466302317414663.
   PubMed Web of Science ®Google Scholar
• Farberg AS, Marson JW, Soleymani T. Advances in photodynamic therapy for the treatment of actinic keratosis and nonmelanoma skin cancer: a narrative review. Dermatol Ther (Heidelb). 2023;13(3):689–716. doi:10.1007/s13555-023-00888-1.
   PubMed Web of Science ®Google Scholar
• Geavlete B, Mulţescu R, Georgescu D, Geavlete P. Hexvix blue light fluorescence cystoscopy–a promising approach in diagnosis of superficial bladder tumors. J Med Life. 2008;1(3):355–362. http://www.ncbi.nlm.nih.gov/pubmed/20108513
   PubMedGoogle Scholar
• Cruess AF, Zlateva G, Pleil AM, Wirostko B. Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties. Acta Ophthalmol. 2009;87(2):118–132. doi:10.1111/j.1755-3768.2008.01218.x.
   PubMed Web of Science ®Google Scholar
• Aveline B, Hasan T, Redmond RW. PHOTOPHYSICAL and PHOTOSENSITIZING PROPERTIES of BENZOPORPHYRIN DERIVATIVE MONOACID RING a (BPD-MA). Photochem Photobiol. 1994;59(3):328–335. doi:10.1111/j.1751-1097.1994.tb05042.x.
   PubMed Web of Science ®Google Scholar
• Houle J-M, Strong A. Clinical Pharmacokinetics of Verteporfin. J Clin Pharmacol. 2002;42(5):547–557. doi:10.1177/00912700222011607.
   PubMed Web of Science ®Google Scholar
• Huggett MT, Jermyn M, Gillams A, Illing R, Mosse S, Novelli M, Kent E, Bown SG, Hasan T, Pogue BW, et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer. 2014;110(7):1698–1704. doi:10.1038/bjc.2014.95.
   PubMed Web of Science ®Google Scholar
• Donohoe C, Senge MO, Arnaut LG, Gomes-da-Silva LC. Cell death in photodynamic therapy: from oxidative stress to anti-tumor immunity. Biochim Biophys Acta - Rev Cancer. 2019;1872(2):188308. doi:10.1016/j.bbcan.2019.07.003.
   PubMed Web of Science ®Google Scholar
• Korbelik M, Sun J. Photodynamic therapy-generated vaccine for cancer therapy. Cancer Immunol Immunother. 2006;55(8):900–909. doi:10.1007/s00262-005-0088-4.
   PubMed Web of Science ®Google Scholar
• Korbelik M. Cancer vaccines generated by photodynamic therapy. Photochem Photobiol Sci. 2011;10(5):664–669. doi:10.1039/c0pp00343c.
   PubMed Web of Science ®Google Scholar
• Vedunova M, Turubanova V, Vershinina O, Savyuk M, Efimova I, Mishchenko T, Raedt R, Vral A, Vanhove C, Korsakova D, et al. DC vaccines loaded with glioma cells killed by photodynamic therapy induce Th17 anti-tumor immunity and provide a four-gene signature for glioma prognosis. Cell Death Disease. 2022;13(12):1062. doi:10.1038/s41419-022-05514-0.
   PubMed Web of Science ®Google Scholar
• Hendrzak-Henion JA, Knisely TL, Cincotta L, Cincotta E, Cincotta AH. Role of the immune system in mediating the antitumor effect of benzophenothiazine photodynamic therapy. Photochem Photobiol. 1999;69(5):575–581. doi:10.1111/j.1751-1097.1999.tb03330.x.
   PubMed Web of Science ®Google Scholar
• Kabingu E, Vaughan L, Owczarczak B, Ramsey KD, Gollnick SO. CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells. Br J Cancer. 2007;96(12):1839–1848. doi:10.1038/sj.bjc.6603792.
   PubMed Web of Science ®Google Scholar
• Korbelik M, Cecic I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett. 1999;137(1):91–98. doi:10.1016/S0304-3835(98)00349-8.
   PubMed Web of Science ®Google Scholar
• Wachowska M, Gabrysiak M, Muchowicz A, Bednarek W, Barankiewicz J, Rygiel T, Boon L, Mroz P, Hamblin MR, Golab J, et al. 5-Aza-2′-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy. Eur J Cancer. 2014;50(7):1370–1381. doi:10.1016/j.ejca.2014.01.017.
   PubMed Web of Science ®Google Scholar
• Kleinovink JW, Fransen MF, Löwik CW, Ossendorp F. Photodynamic-immune checkpoint therapy eradicates local and distant tumors by CD8+ T Cells. Cancer Immunol Res. 2017;5(10):832–838. doi:10.1158/2326-6066.CIR-17-0055.
   PubMed Web of Science ®Google Scholar
• Lobo SA, Gomes-da-Silva LC, Rodrigues-Santos P, Cabrita A, Santos-Rosa M, Arnaut LG. Immune responses after vascular photodynamic therapy with redaporfin. J Clin Med. 2019;9(1):104. doi:10.3390/jcm9010104.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Yin G, Le V, Zhang A, Chen S, Liang X, Liu J. Photodynamic-therapy activates immune response by disrupting immunity homeostasis of tumor cells, which generates vaccine for cancer therapy. Int J Biol Sci. 2016;12(1):120–132. doi:10.7150/ijbs.12852.
   PubMed Web of Science ®Google Scholar
• Mroz P, Vatansever F, Muchowicz A, Hamblin MR. Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A. Cancer Res. 2013;73(21):6462–6470. doi:10.1158/0008-5472.CAN-11-2572.
   PubMed Web of Science ®Google Scholar
• Mroz P, Szokalska A, Wu MX, Hamblin MR. Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response. Mosley RL, ed. PLoS One. 2010;5(12):e15194. doi:10.1371/journal.pone.0015194.
   PubMed Web of Science ®Google Scholar
• Shams M, Owczarczak B, Manderscheid-Kern P, Bellnier DA, Gollnick SO. Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease. Cancer Immunol Immunother. 2015;64(3):287–297. doi:10.1007/s00262-014-1633-9.
   PubMed Web of Science ®Google Scholar
• Cantl G, Lattuada D, Nicolin A, Taroni P, Valentinl G, Cubeddu R. Antitumor immunity induced by photodynamic therapy with aluminum disulfonated phthalocyanines and laser light. Anticancer Drugs. 1994;5(4):443–447. doi:10.1097/00001813-199408000-00009.
   PubMed Web of Science ®Google Scholar
• Preise D, Oren R, Glinert I, Kalchenko V, Jung S, Scherz A, Salomon Y. Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity. Cancer Immunol Immunother. 2009;58(1):71–84. doi:10.1007/s00262-008-0527-0.
   PubMed Web of Science ®Google Scholar
• Yeung H-Y, Lo P-C, Ng DKP, Fong W-P. Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model. Cell Mol Immunol. 2017;14(2):223–234. doi:10.1038/cmi.2015.84.
   PubMed Web of Science ®Google Scholar
• Donohoe C, Schaberle FA, Rodrigues FMS, Gonçalves NPF, Kingsbury CJ, Pereira MM, Senge MO, Gomes-da-Silva LC, Arnaut LG. Unraveling the pivotal role of atropisomerism for cellular internalization. J Am Chem Soc. 2022;144(33):15252–15265. doi:10.1021/jacs.2c05844.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23(4):487–500. doi:10.1038/s41590-022-01132-2.
   PubMed Web of Science ®Google Scholar
• Gollnick SO, Evans SS, Baumann H, Owczarczak B, Maier P, Vaughan L, Wang WC, Unger E, Henderson BW. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer. 2003;88(11):1772–1779. doi:10.1038/sj.bjc.6600864.
   PubMed Web of Science ®Google Scholar
• Cecic I, Parkins CS, Korbelik M. Induction of systemic neutrophil response in mice by photodynamic therapy of solid tumors¶. Photochem Photobiol. 2001;74(5):712. doi:10.1562/0031-8655(2001)074<0712:IOSNRI>2.0.CO;2.
   PubMed Web of Science ®Google Scholar
• Maeding N, Verwanger T, Krammer B. Boosting tumor-specific immunity using PDT. Cancers Basel. 2016;8(10):91. doi:10.3390/cancers8100091.
   PubMed Web of Science ®Google Scholar
• Krosl G, Korbelik M, Dougherty G. Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy. Br J Cancer. 1995;71(3):549–555. doi:10.1038/bjc.1995.108.
   PubMed Web of Science ®Google Scholar
• Kousis PC, Henderson BW, Maier PG, Gollnick SO. Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res. 2007;67(21):10501–10510. doi:10.1158/0008-5472.CAN-07-1778.
   PubMed Web of Science ®Google Scholar
• Garg AD, Vandenberk L, Fang S, Fasche T, Van Eygen S, Maes J, Van Woensel M, Koks C, Vanthillo N, Graf N, et al. Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing. Cell Death Differ. 2017;24(5):832–843. doi:10.1038/cdd.2017.15.
   PubMed Web of Science ®Google Scholar
• Brackett CM, Muhitch JB, Evans SS, Gollnick SO. IL-17 promotes neutrophil entry into tumor-draining lymph nodes following induction of sterile inflammation. J Immunol. 2013;191(8):4348–4357. doi:10.4049/jimmunol.1103621.
   PubMed Web of Science ®Google Scholar
• Lobo CS, Gomes-da-Silva LC, Arnaut LG. Potentiation of systemic anti-tumor immunity with photodynamic therapy using porphyrin derivatives. <source/>. 2022:279–344. doi:10.1142/9789811246760_0222.
   Google Scholar
• Beltrán Hernández I, Yu Y, Ossendorp F, Korbelik M, Oliveira S. Preclinical and clinical evidence of immune responses triggered in oncologic photodynamic therapy: clinical recommendations. J Clin Med. 2020;9(2):333. doi:10.3390/jcm9020333.
   PubMed Web of Science ®Google Scholar
• Falk‐Mahapatra R, Gollnick SO. Photodynamic therapy and immunity: an update. Photochem Photobiol. 2020;96(3):550–559. doi:10.1111/php.13253.
   PubMed Web of Science ®Google Scholar
• Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M, Stern PL, Moore JV, Corbitt G, Kitchener HC, Hampson IN. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res. 2001;61(1):192–196. http://www.ncbi.nlm.nih.gov/pubmed/11196160
   PubMed Web of Science ®Google Scholar
• Adamek M, Kawczyk-Krupka A, Mostowy A, Czuba Z, Krol W, Kasperczyk S, Jakobisiak M, Golab J, Sieron A. Topical ALA–PDT modifies neutrophils’ chemiluminescence, lymphocytes’ interleukin-1beta secretion and serum level of transforming growth factor beta1 in patients with nonmelanoma skin malignancies. Photodiagnosis Photodyn Ther. 2005;2(1):65–72. doi:10.1016/S1572-1000(05)00004-9.
   PubMed Web of Science ®Google Scholar
• Prignano F, Lotti T, Spallanzani A, Berti S, de Giorgi V, Moretti S. Sequential effects of photodynamic treatment of basal cell carcinoma. J Cutan Pathol. 2009;36(4):409–416. doi:10.1111/j.1600-0560.2008.01063.x.
   PubMed Web of Science ®Google Scholar
• Kabingu E, Oseroff AR, Wilding GE, Gollnick SO. Enhanced systemic immune reactivity to a basal cell carcinoma associated antigen following photodynamic therapy. Clin Cancer Res. 2009;15(13):4460–4466. doi:10.1158/1078-0432.CCR-09-0400.
   PubMed Web of Science ®Google Scholar
• Longo C, Casari A, Pepe P, Moscarella E, Zalaudek I, Argenziano G, Pellacani G. Confocal microscopy insights into the treatment and cellular immune response of basal cell carcinoma to photodynamic therapy. Dermatology. 2012;225(3):264–270. doi:10.1159/000345106.
   PubMed Web of Science ®Google Scholar
• Evangelou G, Farrar MD, Cotterell L, Andrew S, Tosca AD, Watson REB, Rhodes LE. Topical photodynamic therapy significantly reduces epidermal Langerhans cells during clinical treatment of basal cell carcinoma. Br J Dermatol. 2012;166(5):1112–1115. doi:10.1111/j.1365-2133.2012.10823.x.
   PubMed Web of Science ®Google Scholar
• Pellegrini C, Orlandi A, Costanza G, Di Stefani A, Piccioni A, Di Cesare A, Chiricozzi A, Ferlosio A, Peris K, Fargnoli MC, et al. Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments. Shiku H, ed. PLoS One. 2017;12(8):e0183415. doi:10.1371/journal.pone.0183415.
   PubMed Web of Science ®Google Scholar
• Reginato E, Lindenmann J, Langner C, Schweintzger N, Bambach I, Smolle-Jüttner F, Wolf P. Photodynamic therapy downregulates the function of regulatory T cells in patients with esophageal squamous cell carcinoma. Photochem Photobiol Sci. 2014;13(9):1281–1289. doi:10.1039/c4pp00186a.
   PubMed Web of Science ®Google Scholar
• Theodoraki MN, Lorenz K, Lotfi R, Fürst D, Tsamadou C, Jaekle S, Mytilineos J, Brunner C, Theodorakis J, Hoffmann TK, et al. Influence of photodynamic therapy on peripheral immune cell populations and cytokine concentrations in head and neck cancer. Photodiagnosis Photodyn Ther. 2017;19:194–201. doi:10.1016/j.pdpdt.2017.05.015.
   PubMed Web of Science ®Google Scholar
• Gu B, Wang B, Li X, Feng Z, Ma C, Gao L, Yu Y, Zhang J, Zheng P, Wang Y, et al. Photodynamic therapy improves the clinical efficacy of advanced colorectal cancer and recruits immune cells into the tumor immune microenvironment. Front Immunol. 2022;13:13. doi:10.3389/fimmu.2022.1050421.
   Web of Science ®Google Scholar
• Thong PSP, Ong K-W, Goh NSG, Kho K-W, Manivasager V, Bhuvaneswari R, Olivo M, Soo K-C. Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma. Lancet Oncol. 2007;8(10):950–952. doi:10.1016/S1470-2045(07)70318-2.
   PubMed Web of Science ®Google Scholar
• Thong PSP, Olivo M, Kho K-W, Bhuvaneswari R, Chin WWL, Ong K-W, Soo K-C. Immune response against angiosarcoma following lower fluence rate clinical photodynamic therapy. J Environ Pathol Toxicol Oncol. 2008;27(1):35–42. doi:10.1615/JEnvironPatholToxicolOncol.v27.i1.40.
   PubMed Web of Science ®Google Scholar
• Cuenca RE, Allison RR, Sibata C, Downie GH. Breast cancer with chest wall progression: treatment with photodynamic therapy. Ann Surg Oncol. 2004;11(3):322–327. doi:10.1245/ASO.2004.03.025.
   PubMed Web of Science ®Google Scholar
• Morrison SA, Hill SL, Rogers GS, Graham RA. Efficacy and safety of continuous low-irradiance photodynamic therapy in the treatment of chest wall progression of breast cancer. J Surg Res. 2014;192(2):235–241. doi:10.1016/j.jss.2014.06.030.
   PubMed Web of Science ®Google Scholar
• Eymerit-Morin C, Zidane M, Lebdai S, Triau S, Azzouzi AR, Rousselet M-C. Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer. Virchows Arch. 2013;463(4):547–552. doi:10.1007/s00428-013-1454-9.
   PubMed Web of Science ®Google Scholar
• Azzouzi A-R, Lebdai S, Benzaghou F, Stief C. Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure. World J Urol. 2015;33(7):937–944. doi:10.1007/s00345-015-1535-2.
   PubMed Web of Science ®Google Scholar
• Kawczyk-Krupka A, Wawrzyniec K, Musiol SK, Potempa M, Bugaj AM, Sieroń A. Treatment of localized prostate cancer using WST-09 and WST-11 mediated vascular targeted photodynamic therapy—A review. Photodiagnosis Photodyn Ther. 2015;12(4):567–574. doi:10.1016/j.pdpdt.2015.10.001.
   PubMed Web of Science ®Google Scholar
• Betrouni N, Boukris S, Benzaghou F. Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning. Lasers Med Sci. 2017;32(6):1301–1307. doi:10.1007/s10103-017-2241-7.
   PubMed Web of Science ®Google Scholar
• Kleinclauss F, Frontczak A, Balssa L, Lebdai S, Azzouzi R. Photothérapie dynamique dans le cancer de la prostate à faible risque. Revue de la littérature Progrès en Urol. 2019;29(8–9):393–401. doi:10.1016/j.purol.2019.05.004.
   PubMedGoogle Scholar
• Agency EM. Tookad: withdrawal of the application to change the marketing authorisation. Accessed 2023 April, 2. https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/tookad
   Google Scholar
• Arnaut LG, Pereira MM, Dąbrowski JM, Silva EFF, Schaberle FA, Abreu AR, Rocha LB, Barsan MM, Urbańska K, Stochel G, et al. Photodynamic therapy efficacy enhanced by dynamics: the role of charge transfer and photostability in the selection of photosensitizers. Chem - A Eur J. 2014;20(18):5346–5357. doi:10.1002/chem.201304202.
   PubMed Web of Science ®Google Scholar
• Santos LL, Oliveira J, Monteiro E, Santos J, Sarmento C. Treatment of head and neck cancer with photodynamic therapy with redaporfin: a clinical case report. Case Rep Oncol. 2018;11(3):769–776. doi:10.1159/000493423.
   PubMed Web of Science ®Google Scholar
• Saavedra R, Rocha LB, Dąbrowski JM, Arnaut LG. Modulation of biodistribution, pharmacokinetics, and photosensitivity with the delivery vehicle of a bacteriochlorin photosensitizer for photodynamic therapy. ChemMedchem. 2014;9(2):390–398. doi:10.1002/cmdc.201300449.
   PubMed Web of Science ®Google Scholar
• Pucelik B, Arnaut LG, Stochel G, Dąbrowski JM. Design of pluronic-based formulation for enhanced redaporfin-photodynamic therapy against pigmented melanoma. ACS Appl Mater Interfaces. 2016;8(34):22039–22055. doi:10.1021/acsami.6b07031.
   PubMed Web of Science ®Google Scholar
• EMA. Orphan designation for the treatment of biliary tract cancer. Accessed 2023 April 2. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2602
   Google Scholar
• Valdés PA, Jacobs V, Harris BT, Wilson BC, Leblond F, Paulsen KD, Roberts DW. Quantitative fluorescence using 5-aminolevulinic acid-induced protoporphyrin IX biomarker as a surgical adjunct in low-grade glioma surgery. J Neurosurg. 2015;123(3):771–780. doi:10.3171/2014.12.JNS14391.
   PubMed Web of Science ®Google Scholar
• Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801. doi:10.1038/s41467-020-17670-y.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254–267. doi:10.1038/s41571-022-00600-w.
   PubMed Web of Science ®Google Scholar
• Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol Mech Dis. 2021;16(1):223–249. doi:10.1146/annurev-pathol-042020-042741.
   PubMed Web of Science ®Google Scholar
• Anand S, Chan T, Hasan T, Maytin E. Current prospects for treatment of solid tumors via photodynamic, photothermal, or ionizing radiation therapies combined with immune checkpoint inhibition (A review). Pharmaceuticals. 2021;14(5):447. doi:10.3390/ph14050447.
   Web of Science ®Google Scholar
• Zhang R, Zhu Z, Lv H, Li F, Sun S, Li J, Lee C-S. Immune checkpoint blockade mediated by a small‐molecule nanoinhibitor targeting the PD‐1/PD‐L1 pathway synergizes with photodynamic therapy to elicit antitumor immunity and antimetastatic effects on breast cancer. Small. 2019;15(49):1903881. doi:10.1002/smll.201903881.
   PubMed Web of Science ®Google Scholar
• Lobo CS, Mendes MIP, Gomes-da-Silva LC, Arnaut L.G, Pereira D.A. 2022. Photodynamic therapy changes tumour immunogenicity and promotes immune-checkpoint blockade response, especially when combined with enhanced tumour infiltration by micromechanical priming. Preprint. Published online 2022. doi:10.21203/rs.3.rs-2201462/v1.
   Google Scholar
• Bao R, Wang Y, Lai J, Zhu H, Zhao Y, Li S, Li N, Huang J, Yang Z, Wang F, et al. Enhancing anti-PD-1/PD-L1 immune checkpoint inhibitory cancer therapy by CD276-targeted photodynamic ablation of tumor cells and tumor vasculature. Mol Pharm. 2019;16(1):339–348. doi:10.1021/acs.molpharmaceut.8b00997.
   PubMed Web of Science ®Google Scholar
• Wang X, Maswikiti EP, Zhu J-Y, Ma Y-L, Zheng P, Yu Y, Wang B-F, Gao L, Chen H. Photodynamic therapy combined with immunotherapy for an advanced esophageal cancer with an obstruction post metal stent implantation: a case report and literature review. Photodiagnosis Photodyn Ther. 2022;37:102671. doi:10.1016/j.pdpdt.2021.102671.
   PubMed Web of Science ®Google Scholar
• Ma C, Ma H, Deng X, Yu R, Song K-W, Wei K-K, Wang C-J, Li H-X, Chen H. Photodynamic therapy in combination with chemotherapy, targeted, and immunotherapy as a successful therapeutic approach for advanced gastric adenocarcinoma: a case report and literature review. Photobiomodulation, Photomed, Laser Surg. 2022;40(5):308–314. doi:10.1089/photob.2021.0167.
   PubMed Web of Science ®Google Scholar
• Schaberle FA, Gomes-da-Silva LC. A network representation of photodynamic therapy aiming the integration of knowledge and boosting clinical acceptance. Photodiagnosis Photodyn Ther. 2022;37:102715. doi:10.1016/j.pdpdt.2022.102715.
   PubMed Web of Science ®Google Scholar
• Nath S, Obaid G, Hasan T. The course of immune stimulation by photodynamic therapy: bridging fundamentals of photochemically induced immunogenic cell death to the enrichment of T‐cell repertoire. Photochem Photobiol. 2019;95(6):1288–1305. doi:10.1111/php.13173.
   PubMed Web of Science ®Google Scholar
• Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2(5):e192535. doi:10.1001/jamanetworkopen.2019.2535.
   PubMed Web of Science ®Google Scholar